The novel β2-selective proteasome inhibitor LU-102 decreases phosphorylation of I kappa B and induces highly synergistic cytotoxicity in combination with ibrutinib in multiple myeloma cells

PURPOSE: Proteasome-inhibiting drugs (PI) are gaining importance in hematologic oncology. The proteasome carries three proteolytically active subunits (β1, β2, β5). All established PI (bortezomib and carfilzomib), as well as experimental drugs in the field (dalanzomib, oprozomib, and ixazomib), by d...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Cancer Chemother Pharmacol
Main Authors: Kraus, Johannes, Kraus, Marianne, Liu, Nora, Besse, Lenka, Bader, Jürgen, Geurink, Paul P., de Bruin, Gerjan, Kisselev, Alexei F., Overkleeft, Herman, Driessen, Christoph
Formato: Artigo
Idioma:Inglês
Publicado: Springer Berlin Heidelberg 2015
Assuntos:
Original Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4515249/
https://ncbi.nlm.nih.gov/pubmed/26099967
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-015-2801-0
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares